NCT03546842已完成3 期
A Phase III Open-label Safety and Immunogenicity Study of GARDASIL™9 Administered to 9- to 26-Year-Old Females and Males in Vietnam
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 201
- 试验地点
- 2
- 主要终点
- Seroconversion Percentages to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 7
研究概览
简要总结
This study will evaluate the safety and immunogenicity of V503 (GARDASIL™9, 9vHPV vaccine) administered to 9- to 26-year-old females and males in Vietnam. The study hypothesis states that V503 induces acceptable anti-human papillomavirus (HPV) 6, 11, 16, 18, 31, 33, 45, 52, and 58 seroconversion at 4 weeks postdose 3.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 9 Years 至 26 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •In good physical health
- •Participants 9 to 15 years of age: has not had coitarche and do not plan on becoming sexually active during the study
- •Participants 16 to 26 year of age: has never had Papanicolaou (Pap) testing or has had only normal Pap test results. Has a lifetime history of ≤4 male and/or female sexual partners.
- •Female participants 16 to 26 years of age: has not had sex with males or has had sex with males and used effective contraception, and understands and agrees that during the study she should not have sexual intercourse with males without effective contraception (rhythm method, withdrawal, and emergency contraception are not acceptable methods of contraception per-protocol).
排除标准
- •Known allergy to any vaccine component, including aluminum, yeast, or BENZONASE™
- •History of severe allergic reaction that required medical intervention
- •Has thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections
- •Concurrently enrolled in clinical studies of investigational agents
- •Immunocompromised or has been diagnosed with congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition
- •Had a splenectomy
- •User of recreational or illicit drugs or has had a recent history (within the last year) of drug abuse or dependence. Alcohol abusers are defined as those who drink despite recurrent social, interpersonal, and/or legal problems as a result of alcohol use.
- •History of a positive test for HPV
- •Male participants 16 to 26 years of age: history of HPV-related external genital lesions (e.g., condyloma acuminata) or HPV-related anal lesions (e.g., condyloma acuminata, or anal intraepithelial neoplasia) or anal cancer.
- •Female participants 16 to 26 years of age: history of an abnormal cervical biopsy result (showing cervical intraepithelial neoplasia or worse).
- •Female participants 16 to 26 years of age: history of HPV-related external genital lesions (e.g., condyloma acuminata, or vulvar intraepithelial neoplasia) or external genital cancer, HPV-related vaginal lesions (e.g., condyloma acuminata, or vaginal intraepithelial neoplasia) or vaginal cancer, or HPV-related anal lesions (e.g., condyloma acuminata, or anal intraepithelial neoplasia) or anal cancer.
- •Female participants: pregnant as determined by a serum pregnancy test or urine pregnancy test that is sensitive to 25 mIU/mL beta human chorionic gonadotropin (β-hCG).
- •Female participants: expecting to donate eggs during the study.
- •Receiving or has received a prohibited immunosuppressive therapy in the year prior to the study
- •Received any immune globulin product or blood-derived product within the 3 months prior to the Day 1 vaccination, or plans to receive any such product during the study
- •Received inactivated or recombinant vaccines within 14 days prior to the Day 1 vaccination or has received live vaccines within 21 days prior to the Day 1 vaccination
- •Received a marketed HPV vaccine, or has participated in an HPV vaccine clinical study and has received either active agent or placebo
- •Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational site or sponsor staff directly involved with this study.
结局指标
主要结局
Seroconversion Percentages to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 7
时间窗: 4 weeks postdose 3 (Month 7)
Seroconversion was defined as a participant who was anti-HPV seronegative at Day 1 and became seropositive at 4 weeks postdose 3 (Month 7). Anti-HPV antibodies were measured using a Competitive Luminex Immunoassay.
次要结局
- Percentage of Participants With a Vaccine-related Serious Adverse Event(Up to 4 weeks postdose 3 (Month 7))
- Geometric Mean Titers of Serotype-specific Antibodies: Predose Day 1(Day 1 (predose))
- Percentage of Participants With a Solicited Injection-site Adverse Event(Up to 5 days after any vaccination)
- Percentage of Participants With a Solicited Systemic Adverse Event(Up to 5 days after any vaccination)
- Geometric Mean Titers of Antibodies to HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 7(4 weeks postdose 3 (Month 7))
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
3 期
V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)Papillomavirus InfectionsNCT05450705Merck Sharp & Dohme LLC1,500
招募中
3 期
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 YearsHPV InfectionsCIN1CIN2CIN 3VaIN1VaIN2VaIN3Cervical CancerVulvar CancerGenital WartVIN 1VIN 2VIN 3AISVaginal CancerNCT04895020Shanghai Bovax Biotechnology Co., Ltd.1,200
进行中（未招募）
3 期
Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)Genital WartsNCT05314023Merck Sharp & Dohme LLC1,590
已完成
3 期
A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)Cervical CancersGenital LesionsPAP Test AbnormalitiesHPV InfectionsVulvar CancerVaginal CancerNCT00943722Merck Sharp & Dohme LLC3,074
已完成
3 期
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)Papillomavirus InfectionsCoronavirus Disease (COVID-19)NCT05119855Merck Sharp & Dohme LLC165